Sanjib Saha
Senior Scientist, Advanced Drug Delivery AstraZeneca
Dr. Sanjib Saha currently working as a Senior Scientist in Advanced Drug Delivery (ADD) group at AstraZeneca Pharmaceuticals (R&D Boston, USA). Throughout his professional career, he has developed deep expertise in a wide range of novel drug delivery technologies, with a special emphasis on lipid nanoparticles for the targeted delivery of nucleic acids. His research focuses on the rational design of targeted delivery systems to develop next generation therapeutics.
Seminars
- How to optimize screening approaches to rapidly evaluate large libraries of LNP compositions and identify candidates with enhanced extrahepatic tropism?
- What screening approaches are most effective for selecting and testing targeting moieties to ensure high specificity, manufacturability, and reproducible performance after LNP conjugation?
- How can AI/ML and predictive models be integrated into experimental screening workflows to improve lipid and ligand selection?
Unlike traditional LNPs, targeted LNPs introduce additional layers of analytical, process, and CMC complexity due to surface-bound ligands and multi-step modifications. This workshop will examine how to align analytical development with process development and scale-up strategies to manage this complexity, ensure high product quality, and enable reliable manufacturing.
This workshop will gather experts to discuss:
- Unlocking advanced analytics for tLNPs to quantify conjugated binders, assess particle heterogeneity, and confirming ligand integrity following large-scale manufacturing
- De-risking batch-to-batch variability and maintaining CQA consistency by designing conjugation chemistry and manufacturing processes achieving uniform ligand attachment
- Navigating scale-up of tLNPs by addressing added downstream, analytical, and stability of targeting challenges not seen with traditional LNPs
